KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Gains from Investment Securities (2016 - 2024)

Nektar Therapeutics has reported Gains from Investment Securities over the past 15 years, most recently at -$7.6 million for Q4 2024.

  • Quarterly results put Gains from Investment Securities at -$7.6 million for Q4 2024, down 93.0% from a year ago — trailing twelve months through Dec 2024 was $76000.0 (up 105.85% YoY), and the annual figure for FY2025 was -$195000.0, down 356.58%.
  • Gains from Investment Securities for Q4 2024 was -$7.6 million at Nektar Therapeutics, down from $2.1 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for NKTR hit a ceiling of $6.7 million in Q4 2021 and a floor of -$7.6 million in Q4 2024.
  • Median Gains from Investment Securities over the past 5 years was $93500.0 (2022), compared with a mean of $32200.0.
  • Peak annual rise in Gains from Investment Securities hit 345.22% in 2023, while the deepest fall reached 3856.0% in 2023.
  • Nektar Therapeutics' Gains from Investment Securities stood at $1.7 million in 2020, then soared by 298.7% to $6.7 million in 2021, then plummeted by 101.49% to -$100000.0 in 2022, then plummeted by 3856.0% to -$4.0 million in 2023, then plummeted by 93.0% to -$7.6 million in 2024.
  • The last three reported values for Gains from Investment Securities were -$7.6 million (Q4 2024), $2.1 million (Q3 2024), and $2.6 million (Q2 2024) per Business Quant data.